Last reviewed · How we verify
Anti-Tuberculosis Treatment
Anti-tuberculosis treatments work by inhibiting bacterial cell wall synthesis, protein synthesis, or DNA replication in Mycobacterium tuberculosis.
Anti-tuberculosis treatments work by inhibiting bacterial cell wall synthesis, protein synthesis, or DNA replication in Mycobacterium tuberculosis. Used for Tuberculosis (drug-susceptible and drug-resistant forms).
At a glance
| Generic name | Anti-Tuberculosis Treatment |
|---|---|
| Also known as | DOT CAT II |
| Sponsor | NMP Medical Research Institute |
| Drug class | Anti-tuberculosis agent |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Anti-TB drugs typically target essential bacterial processes that are absent or structurally different in human cells, allowing selective toxicity. Common mechanisms include inhibition of mycolic acid synthesis (isoniazid, ethambutol), RNA polymerase (rifampicin), or protein synthesis (streptomycin, fluoroquinolones). Combination therapy is used to prevent resistance development.
Approved indications
- Tuberculosis (drug-susceptible and drug-resistant forms)
Common side effects
- Hepatotoxicity
- Peripheral neuropathy
- Gastrointestinal disturbance
- Rash
- Ototoxicity
Key clinical trials
- Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) (PHASE2)
- Treatment of Tuberculosis Multidrug Resistance Treatment of Tuberculosis Multidrug Resistance
- AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT (PHASE2)
- Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB (PHASE2)
- Evaluation of a Novel Microbiological Diagnostic Test for Latent Mycobacterium Tuberculosis Infection
- Effect of Peer-led Educational Intervention on Treatment Outcomes Among Adults With Drug-susceptible Pulmonary Tuberculosis in South Omo and Ari Zone, Southern Ethiopia (NA)
- Asymptomatic TB With Innovative Modified Short-course Regimens (PHASE4)
- Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-Tuberculosis Treatment CI brief — competitive landscape report
- Anti-Tuberculosis Treatment updates RSS · CI watch RSS
- NMP Medical Research Institute portfolio CI